Last $6.04 USD
Change Today 0.00 / 0.00%
Volume 17.1K
CBRX On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
As of 8:10 PM 09/15/14 All times are local (Market data is delayed by at least 15 minutes).

columbia laboratories inc (CBRX) Snapshot

Open
$6.07
Previous Close
$6.04
Day High
$6.08
Day Low
$6.02
52 Week High
09/16/13 - $7.76
52 Week Low
08/4/14 - $5.59
Market Cap
65.1M
Average Volume 10 Days
32.9K
EPS TTM
$-0.15
Shares Outstanding
10.8M
EX-Date
--
P/E TM
--
Dividend
$1.00
Dividend Yield
--
Current Stock Chart for COLUMBIA LABORATORIES INC (CBRX)

Related News

No related news articles were found.

columbia laboratories inc (CBRX) Related Businessweek News

No Related Businessweek News Found

columbia laboratories inc (CBRX) Details

Columbia Laboratories, Inc. provides pharmaceutical development, clinical trial manufacturing, and analytical and consulting services to the pharmaceutical industry. It focuses on the sale of CRINONE, a progesterone gel to its marketing partner. The company has licensed CRINONE to Merck Serono S.A. outside the United States; and has sold the rights to CRINONE to Actavis, Inc. in the United States. Columbia Laboratories, Inc. was founded in 1986 and is headquartered in Boston, Massachusetts.

77 Employees
Last Reported Date: 03/5/14
Founded in 1986

columbia laboratories inc (CBRX) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $340.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $271.1K
Director and Chief Executive Officer of Molec...
Total Annual Compensation: $86.0K
Compensation as of Fiscal Year 2013.

columbia laboratories inc (CBRX) Key Developments

Columbia Laboratories Announces Completion of CRINONE License Renewal

Columbia Laboratories Inc. announced that Merck Serono has completed a routine license renewal for CRINONE in one of its biggest markets. Normalized shipments are expected to resume at the beginning of 2015. The new license will be in place for five years.

Columbia Laboratories Inc. Announces Unaudited Consolidated Earnings Results for Second Quarter and Six Months Ended June 30, 2014; Revised Revenue Guidance for the Year 2014

Columbia Laboratories Inc. announced unaudited consolidated earnings results for second quarter and six months ended June 30, 2014. For the quarter, the company reported total net revenues of $6,857,000, income from operations of $282,000, income before income taxes of $359,000, net income of $193,000 or $0.01 per diluted share, adjusted EBITDA of $1,001,000 compared to the total net revenues of $7,978,000, income from operations of $2,828,000, income before income taxes of $2,660,000, net income of $2,657,000 or $0.24 per diluted share, adjusted EBITDA of $3,437,000 for the same quarter a year ago. Second quarter results benefited from the contribution of the Molecular Profiles services business, as its diversified revenue stream partially offset an anticipated and temporary decline in product revenues from Merck Serono during a routine license renewal in one high-volume, high-margin market. Throughout the renewal process, no product shipments are permitted in this market. For the six months period, the company reported total net revenues of $14,105,000, income from operations of $406,000, income before income taxes of $800,000, net income of $622,000 or $0.02 per diluted share, adjusted EBITDA of $1,779,000 compared to the total net revenues of $14,294,000, income from operations of $3,842,000, income before income taxes of $3,905,000, net income of $3,899,000 or $0.35 per diluted share, adjusted EBITDA of $5,349,000 for the same period a year ago. The company's prior earnings guidance for potential full year 2014 revenues assumed that the routine license renewal would conclude in first half of the year, with normalized CRINONE shipments resuming in the second half of the year. As normalized shipments are now not expected to resume until early 2015, the company is lowering its expected total revenue growth range for fiscal 2014 from an increase of 8% to 12% to an increase of 6% to 8%.

Columbia Laboratories Inc., Q2 2014 Earnings Call, Jul 31, 2014

Columbia Laboratories Inc., Q2 2014 Earnings Call, Jul 31, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CBRX:US $6.04 USD 0.00

CBRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $42.72 USD +0.17
View Industry Companies
 

Industry Analysis

CBRX

Industry Average

Valuation CBRX Industry Range
Price/Earnings 20.7x
Price/Sales 2.3x
Price/Book 1.6x
Price/Cash Flow 19.0x
TEV/Sales 1.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact COLUMBIA LABORATORIES INC, please visit www.columbialabs.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.